17 citations,
January 1995 in “The American Journal of Medicine”
The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgenreceptors in hair follicles, potentially offering fewer side effects.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.